[Advancement on thrombolytic characteristic, function and clinical application of different fibrinolytic enzymes].
Cardio-cerebral vascular diseases endanger people's health very seriously. Thrombolytic therapy is effective in curing thrombotic diseases at present. Microorganism is an important source of thrombolytic drug. Plasminogen activators are widely used as thrombolytic drugs clinically, while they are still exists some defects. This article analyzed research and development status of kinds of thrombolytic drugs from microorganisms, and evaluated their clinical efficacy and safety, aiming at showing the direction to search new and effective thrombolytic drugs and prevent and treat thromboembolic disease.
Sun
Yuee
Y
College of Food Engineering, Xuzhou Institute of Technology, Xuzhou 221008, China. sunyuee416@yahoo.com.cn
Wang
Weidong
W
Li
Chao
C
D001419:Bacteria / Q000201:enzymology; D002985:Clinical Protocols / Q000145:classification; D055808:Drug Discovery / Q000379:methods*; D004359:Drug Therapy, Combination / Q000379:methods; D005343:Fibrinolytic Agents / Q000138:chemical synthesis / Q000302:isolation & purification* / Q000600:supply & distribution / Q000627:therapeutic use*; D006801:Humans; D010960:Plasminogen Activators / Q000600:supply & distribution / Q000627:therapeutic use; D013923:Thromboembolism / Q000188:drug therapy; D015912:Thrombolytic Therapy / Q000379:methods; D013927:Thrombosis / Q000188:drug therapy*; D014568:Urokinase-Type Plasminogen Activator / Q000302:isolation & purification / Q000627:therapeutic use; D014780:Viruses / Q000737:chemistry / Q000201:enzymology
D005343:Fibrinolytic Agents; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator